Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We have identified 2 antigens recognized by several melanoma-specific cytolytic T lymphocyte clones isolated from a melanoma patient with a clinical history of tumor regression after immunotherapy. Both antigens are presented by HLA-A2 and encoded by gene MAGE-C2, a cancer-germline gene shown previously to be silent in normal somatic tissues and expressed in 40% of melanomas and in other tumor types. One antigen corresponds to peptide ALKDVEERV(336-344), whereas the other corresponds to peptide LLFGLALIEV(191-200). The CTL clones recognizing these 2 peptides also recognized allogeneic tumor cell lines expressing MAGE-C2 and HLA-A2. These 2 new peptides are the first known MAGE-C antigens and represent promising targets for cancer immunotherapy.

Original publication

DOI

10.1002/ijc.20038

Type

Journal article

Journal

Int J Cancer

Publication Date

01/05/2004

Volume

109

Pages

698 - 702

Keywords

Amino Acid Sequence, Antigens, Neoplasm, DNA, Complementary, DNA, Neoplasm, HLA-A2 Antigen, Humans, Lymphatic Metastasis, Melanoma, Molecular Sequence Data, Neoplasm Proteins, Reverse Transcriptase Polymerase Chain Reaction, T-Lymphocytes, Cytotoxic